On Friday, Bristol-Myers Squibb Co. (NYSE: BMY) was -1.71% down from the session before settling in for the closing price of $49.12. A 52-week range for BMY has been $47.58 – $70.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 16.92% over the last five years. When this article was written, the company’s average yearly earnings per share was at -90.71%. With a float of $2.03 billion, this company’s outstanding shares have now reached $2.03 billion.
The firm has a total of 34100 workers. Let’s measure their productivity.
Bristol-Myers Squibb Co. (BMY) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Bristol-Myers Squibb Co. stocks. The insider ownership of Bristol-Myers Squibb Co. is 0.08%, while institutional ownership is 78.17%. The most recent insider transaction that took place on Dec 05 ’23, was worth 99,560. In this transaction Chief Executive Officer of this company bought 2,000 shares at a rate of $49.78, taking the stock ownership to the 82,672 shares. Before that another transaction happened on Nov 28 ’23, when Company’s Chief Executive Officer bought 3,071 for $48.86, making the entire transaction worth $150,049. This insider now owns 79,384 shares in total.
Bristol-Myers Squibb Co. (BMY) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 9.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -90.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.17% during the next five years compared to 5.14% growth over the previous five years of trading.
Bristol-Myers Squibb Co. (NYSE: BMY) Trading Performance Indicators
You can see what Bristol-Myers Squibb Co. (BMY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.17. Likewise, its price to free cash flow for the trailing twelve months is 7.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.86, a number that is poised to hit -4.43 in the next quarter and is forecasted to reach 7.06 in one year’s time.
Technical Analysis of Bristol-Myers Squibb Co. (BMY)
Analysing the last 5-days average volume posted by the [Bristol-Myers Squibb Co., BMY], we can find that recorded value of 11.5 million was lower than the volume posted last year of 16.02 million. As of the previous 9 days, the stock’s Stochastic %D was 0.32%. Additionally, its Average True Range was 0.99.
During the past 100 days, Bristol-Myers Squibb Co.’s (BMY) raw stochastic average was set at 9.39%, which indicates a significant increase from 0.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.90% in the past 14 days, which was higher than the 20.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.15, while its 200-day Moving Average is $54.89. Now, the first resistance to watch is $48.83. This is followed by the second major resistance level at $49.37. The third major resistance level sits at $49.66. If the price goes on to break the first support level at $48.00, it is likely to go to the next support level at $47.71. Should the price break the second support level, the third support level stands at $47.17.
Bristol-Myers Squibb Co. (NYSE: BMY) Key Stats
There are 2,026,759K outstanding shares of the company, which has a market capitalization of 97.85 billion. As of now, sales total 45,006 M while income totals 8,025 M. Its latest quarter income was 11,477 M while its last quarter net income were 1,762 M.
